life at vaccitech
Treating and Preventing Disease
We discover and develop immunotherapeutics products and vaccines for the treatment and prevention of infectious diseases and cancer
Vaccitech is a spin-out company from the University of Oxford’s Jenner Institute, one of the most prestigious vaccine research centres in the world.
Vaccitech today announced the closing of its initial public offering in the United States of 6,500,000 American Depositary Shares (“ADSs”) representing 6,500,000 ordinary shares at an initial public offering price of $17.00 per ADS.
Teaching the immune system to confront deadly infections
Traditional vaccine technology creates a pronounced antibody response to the infectious agent. Vaccitech’s platform is also able to induce potent and durable T cell responses from the cellular arm of the immune system.